8-KEarnings & ResultsFinancial EventsExhibits & Filings

Merck & Co., Inc. 8-K Report, Financial Results (Apr 30, 2019)

Filed April 30, 2019For Securities:MRK

Summary

Merck & Co., Inc. (MRK) filed an 8-K on April 30, 2019, reporting on its financial condition and results for the first quarter of 2019. The filing primarily incorporates by reference a press release and supplemental information detailing the company's Q1 2019 earnings. Investors should note the announcement of a new global restructuring program, the '2019 Restructuring Program,' aimed at optimizing manufacturing and supply networks and reducing real estate footprint. This restructuring initiative is expected to incur cumulative pre-tax costs between $800 million and $1.2 billion, with substantial completion anticipated by the end of 2023. Approximately 55% of these costs are expected to be cash outlays, while the remainder will be non-cash charges. Merck expects to record approximately $500 million in GAAP charges related to this program in 2019, with $187 million already recognized in the first quarter. Crucially, these restructuring charges are not expected to impact the company's non-GAAP financial results, providing clarity for investors focused on operational performance.

Key Highlights

  • 1Merck announced its first quarter 2019 financial results via an 8-K filing on April 30, 2019.
  • 2The company launched a new '2019 Restructuring Program' focused on optimizing its manufacturing, supply network, and real estate footprint.
  • 3The 2019 Restructuring Program is estimated to cost between $800 million and $1.2 billion in pre-tax charges.
  • 4Program completion is expected by the end of 2023, with about 55% of costs being cash outlays.
  • 5Merck anticipates recording approximately $500 million in GAAP charges for this program in 2019, including $187 million in Q1.
  • 6The restructuring charges will not affect Merck's non-GAAP financial results.

Frequently Asked Questions

This 8-K filing does not directly present the first quarter 2019 financial results but incorporates them by reference through an attached press release (Exhibit 99.1) and supplemental information (Exhibit 99.2). Investors should refer to these exhibits for detailed financial performance.

The 2019 Restructuring Program is a new global initiative by Merck to optimize its manufacturing and supply chain operations and reduce its real estate holdings. It is expected to incur pre-tax costs ranging from $800 million to $1.2 billion, with approximately $500 million anticipated to be recorded as GAAP charges in 2019. However, these charges will not affect Merck's non-GAAP financial results.

The company expects the actions contemplated under the 2019 Restructuring Program to be substantially completed by the end of 2023.

The filing states that Merck's non-GAAP financial results will not be affected by the restructuring charges. Investors often focus on non-GAAP measures for operational performance, so while GAAP charges will be recorded, the impact on the company's adjusted earnings may be mitigated.